» Articles » PMID: 16702898

Early Predictors of Substantial Weight Gain in Bipolar Patients Treated with Olanzapine

Overview
Specialty Pharmacology
Date 2006 May 17
PMID 16702898
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

To determine predictors of substantial weight gain (SWG) during treatment of bipolar disorder with olanzapine, data were pooled from 4 long-term randomized, multicenter studies in patients with bipolar mania or mixed mania (N = 948 at initiation of olanzapine). SWG was defined as gaining 5 kg or 7% of initial weight in 30 +/- 2 weeks. Logistic regression estimated odds ratios associated with early weight gain and baseline risk factors for predicting SWG. A classification system to identify patients at risk for SWG was constructed by recursive data partitioning. Baseline characteristics significantly associated with SWG included younger age, nonwhite ethnicity, lower body mass index (BMI), nonrapid cycling, and psychotic features. Weight gain of 2 or more kg in the first 3 weeks of therapy predicted SWG by 30 weeks (sensitivity = 57%; specificity = 71%). A classification system with thresholds for early weight gain, baseline BMI, and ethnicity further improved SWG predictability (sensitivity = 79%; specificity = 70%). In conclusion, patients with bipolar disorder who gained 2 to 3 kg during the first 3 weeks of treatment with olanzapine, SWG was predicted after 30 weeks of treatment. Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation.

Citing Articles

Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.

Bauschka M, Watters A, Blalock D, Farooq A, Mehler P, Gibson D J Eat Disord. 2023; 11(1):215.

PMID: 38057934 PMC: 10699020. DOI: 10.1186/s40337-023-00941-6.


Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study.

Kutzelnigg A, Kopeinig M, Chen C, Fabian A, Pujol-Luna M, Shin Y Int J Bipolar Disord. 2014; 2(1):13.

PMID: 25360398 PMC: 4206769. DOI: 10.1186/s40345-014-0013-x.


Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.

Xue H, Liu L, Zhang H, Montgomery W, Treuer T Neuropsychiatr Dis Treat. 2014; 10:841-64.

PMID: 24876777 PMC: 4037301. DOI: 10.2147/NDT.S58096.


Almost all antipsychotics result in weight gain: a meta-analysis.

Bak M, Fransen A, Janssen J, van Os J, Drukker M PLoS One. 2014; 9(4):e94112.

PMID: 24763306 PMC: 3998960. DOI: 10.1371/journal.pone.0094112.


A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.

Deligiannidis K, Rothschild A, Barton B, Kroll-Desrosiers A, Meyers B, Flint A J Clin Psychiatry. 2013; 74(10):1003-9.

PMID: 24229753 PMC: 3966190. DOI: 10.4088/JCP.13m08400.